Quasar partners with MedNet GmbH, a Germany-based, international service provider for the medical contract manufacturing industry.
We are happy to announce the opening of our new manufacturing facility in Dongguan, China. The facility is now in the validation phase and will fully operational for mass production during Q1-2018. The new facility is our newest asset in our effort to deliver higher quality and newer technologies for innovative medical device mass production and process-design services. Share With Colleagues [sharethis-inline-buttons]
In Dec 2016, BSI Auditors pored over DHRs, validations and quality objectives; then toured the lines and reviewed procedures during Quasar’s annual audit. We are happy to announce that Quasar was found ISO 13485 compliant, surpassing requirements in every category.
An FDA audit was conducted from October 31 to November 3 at the Quasar manufacturing facility in Shenzhen. This is the second consecutive audit Quasar has passed, by the FDA, and the result with NO findings in non-conformance (no 483) endorses Quasar’s renewed commitment to being a qualified medical device manufacturer. Consistent with Quasar’s legacy of maintaining high quality standards, quality is focused on throughout the entire production process, starting from development, and maintained through all phases to manufacturing.
Obamacare and Europe’s economic situation are exerting significant cost pressures on Medical Devices. Leading manufacturers are meeting these pressures with semi and full automation, even at their low-cost locations. The benefits are
The market for medical devices is growing rapidly, requiring the highly skilled manual assembly of numerous components. This specialized assembly and production necessitates a trusted manufacturing partner.